Thoracic Aortic Aneurysm Clinical Trials

Find Thoracic Aortic Aneurysm Clinical Trials Near You

Exploratory Study of Thoracoabdominal Artery Stent Graft System in the Treatment of Thoracoabdominal Aortic Aneurysms

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study is designed as a single-center, prospective, single-arm, open-label, exploratory study. The objective is to evaluate the feasibility of Thoracoabdominal Artery Stent Graft System for endovascular treatment of Thoracoabdominal aortic aneurysms (TAAA).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Age: 18 to 80 years old;

• Patients diagnosed with a Thoracoabdominal aortic aneurysm (based on the modified Crawford classification and European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms), and should meet at least ONE of the following conditions:

‣ Maximum diameter of TAAA is \>50 mm;

⁃ TAAA diameter increases by more than 5 mm in the past 6 months or by more than 10 mm in the past 1 year;

⁃ Definite symptoms associated with TAAA, such as abdominal pain and back pain.

• Anatomical Criteria

‣ Proximal landing zone (aorta or implanted graft): the diameter ranges from 17 to 36 mm, and length should be ≥25 mm;

⁃ Distal landing zone (aorta or implanted graft): If distal landing zone is in iliac artery, distal landing zone diameter ranges from 7 to 25 mm, and length should be ≥15 mm; If the distal landing zone is in the abdominal aorta, distal landing zone diameter ranges from 12 to 36 mm, and length should be ≥20 mm.

⁃ Visceral branch landing zone: the diameter ranges from 6 to 13 mm, and the length should be ≥15 mm;

⁃ Renal artery landing zone: the diameter ranges from 4.5 to 9 mm, and the length should be ≥15 mm;

⁃ Appropriate iliac, femoral, and upper limb arterial access.

• Patients who understand the purpose of the study, volunteer to participate and sign the informed consent form, and are willing to complete follow-up as required by the protocol;

• Patients do not want to or cannot wait for the approved alternative

Locations
Other Locations
Germany
Asklepios Klinik Nord Heidberg
RECRUITING
Hamburg
Contact Information
Primary
Rae Gong
gongrui@lifetechmed.com
+86 18820162460
Time Frame
Start Date: 2025-07-24
Estimated Completion Date: 2031-02
Participants
Target number of participants: 11
Treatments
Experimental: Endovascular therapy used as treatment of TAAA
Traditional methods of treatment of TAAA include open surgery and hybrid surgery. Open surgery requires Thoracoabdominal incision which will result in a huge wound and the reconstruction of the visceral artery is also complicated. endovascular therapy has been developed for many years and has demonstrated significant advantages, such as small wounds, and fewer complications. Now Endovascular therapy is gradually used in the treatment of TAAA as well. Compared with traditional open surgery and hybrid surgery, the risk-benefit ratio of endovascular therapy is much better. When the risk-benefit gap between the investigational device and existing treatments is so wide that a control group is ethically unfeasible. So a single-arm exploratory study is adopted.
Related Therapeutic Areas
Sponsors
Leads: Lifetech Scientific (Shenzhen) Co., Ltd.

This content was sourced from clinicaltrials.gov